Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis
- 4 June 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (2), 257-263
- https://doi.org/10.1016/j.jcf.2020.05.008
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation
- National Institutes of Health
This publication has 17 references indexed in Scilit:
- Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary ExacerbationsAnnals of the American Thoracic Society, 2018
- Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosisEmergencias, 2016
- IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosisJournal of Cystic Fibrosis, 2015
- eulerAPE: Drawing Area-Proportional 3-Venn Diagrams Using EllipsesPLOS ONE, 2014
- Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosisPediatric Pulmonology, 2012
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEuropean Respiratory Journal, 2012
- Approach to treating cystic fibrosis pulmonary exacerbations varies widely across us CF care centersPediatric Pulmonology, 2011
- Cystic Fibrosis Pulmonary GuidelinesAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesisThorax, 2007
- Cystic fibrosisThe Lancet, 2003